We show that a number of patients exhibit somatic mutations of OPCML. In order to understand how these clinical mutations might interfere with OPCML’s tumor suppressor activity we then determine the crystal structure of OPCML and show that these mutations fall into several classes based on mutation type and location on the protein structure. The gene discussed is OPCML; the disease is neoplasm.